Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CDTX Cidara Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CDTX
Price (delayed)
$24.05
Market cap
$311.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$26.09
Enterprise value
$140.11M
Cidara Therapeutics Inc. isa is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its
Highlights
CDTX's debt is down by 42% YoY and by 25% QoQ
The EPS has grown by 2.5% since the previous quarter
The gross profit has plunged by 98% YoY and by 76% from the previous quarter
The company's revenue has shrunk by 98% YoY and by 76% QoQ
Key stats
What are the main financial stats of CDTX
Market
Valuations
Earnings
Shares outstanding
12.97M
Market cap
$311.92M
Enterprise value
$140.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
1,129.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
463.93
Revenue
$302,000
Gross profit
$302,000
Operating income
-$192.83M
Net income
-$182.98M
EBIT
-$182.98M
EBITDA
-$181.59M
Free cash flow
-$191.76M
Per share
Balance sheet
Liquidity
EPS
-$26.09
EPS diluted
-$26.09
Free cash flow per share
-$13.53
Book value per share
$12.93
Revenue per share
$0.02
TBVPS
$13.52
Total assets
$191.73M
Total liabilities
$50.05M
Debt
$2.67M
Equity
$141.68M
Working capital
$140.04M
Debt to equity
0.02
Current ratio
3.87
Quick ratio
3.61
Net debt/EBITDA
0.95
Margins
Efficiency
Dividend
EBITDA margin
-60,129.1%
Gross margin
100%
Net margin
-60,589.7%
Operating margin
-63,850.7%
Return on assets
-98.6%
Return on equity
-132.7%
Return on invested capital
N/A
Return on capital employed
-128%
Return on sales
-60,589.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CDTX stock price
How has the Cidara Therapeutics stock price performed over time
Intraday
3.22%
1 week
5.99%
1 month
10.88%
1 year
94.89%
YTD
-10.53%
QTD
11.65%
Financial performance
How have Cidara Therapeutics's revenue and profit performed over time
Revenue
$302,000
Gross profit
$302,000
Operating income
-$192.83M
Net income
-$182.98M
Gross margin
100%
Net margin
-60,589.7%
The gross profit has plunged by 98% YoY and by 76% from the previous quarter
The company's revenue has shrunk by 98% YoY and by 76% QoQ
Cidara Therapeutics's operating income has decreased by 9% QoQ
CDTX's net income is down by 8% QoQ
Price vs fundamentals
How does CDTX's price correlate with its fundamentals
Growth
What is Cidara Therapeutics's growth rate over time
Valuation
What is Cidara Therapeutics stock price valuation
P/E
N/A
P/B
1.86
P/S
1,129.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
463.93
The EPS has grown by 2.5% since the previous quarter
CDTX's price to book (P/B) is 86% higher than its last 4 quarters average of 1.0
CDTX's equity is down by 13% since the previous quarter
The company's revenue has shrunk by 98% YoY and by 76% QoQ
Efficiency
How efficient is Cidara Therapeutics business performance
Cidara Therapeutics's return on assets has shrunk by 71% YoY but it has increased by 12% QoQ
Cidara Therapeutics's return on equity has increased by 23% QoQ
Dividends
What is CDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CDTX.
Financial health
How did Cidara Therapeutics financials performed over time
Cidara Therapeutics's total liabilities has decreased by 29% YoY and by 2.8% QoQ
The total assets has contracted by 11% from the previous quarter
CDTX's debt is 98% lower than its equity
Cidara Therapeutics's debt to equity has soared by 108% YoY
CDTX's debt is down by 42% YoY and by 25% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.